Digestive Diseases
| Ulcerative colitis
Digestive Diseases
Ulcerative colitis
Early symptomatic improvement with guselkumab induction treatment in moderately to severely active ulcerative colitis: Results from the Phase 3 QUASAR induction study.
book_2
Source:
UEG Week 2023 - Poster session
calendar_today
Published on Medfyle:
November 2023
In this medfyle
Rapid symptomatic relief is an important treatment goal for patients with UC and results from the Phase 3 QUASAR induction study demonstrate the effectiveness of guselkumab in improving symptoms for patients with moderately to severely active UC as early as one week after the first dose, with symptomatic improvements continuing to increase through Week 12.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the UEG Week 2023.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content.
©2023 Infomedica-Medfyle. All rights reserved.
